Business context and reporting period
Entity discrepancy: Although the request identifies Accendra Health Inc., the supplied Form 10-Q is for Owens & Minor, Inc. and its subsidiaries. This summary reflects the filing provided. The quarter ended September 30, 2015; comparisons are with the corresponding 2014 period. Owens & Minor distributes medical and surgical supplies and provides healthcare logistics, kitting and related services through Domestic and International segments.
Financial performance and position
Amounts below are in U.S. dollars; financial statement amounts are rounded to millions unless stated otherwise.
| Metric | Third quarter 2015 | Third quarter 2014 | Nine months 2015 | Nine months 2014 |
|---|---|---|---|---|
| Revenue | $2,471.7 million | $2,386.1 million | $7,285.0 million | $6,948.4 million |
| Gross margin | $306.4 million; 12.39% | $292.5 million; 12.26% | $902.3 million; 12.39% | $856.0 million; 12.32% |
| Operating earnings, GAAP | $53.6 million | $35.4 million | $142.4 million | $118.8 million |
| Net income | $28.2 million | $7.2 million | $71.3 million | $52.5 million |
| Diluted EPS | $0.45 | $0.11 | $1.14 | $0.84 |
| Adjusted diluted EPS (non-GAAP) | $0.54 | $0.42 | $1.44 | $1.26 |
- Cash flow: Nine-month operating cash flow was $206.0 million, versus $81.1 million in 2014. Investing used $32.1 million and financing used $103.1 million. Cash increased by $68.5 million to $125.2 million.
- Liquidity and debt: Current assets were $1,928.4 million and current liabilities $1,067.6 million at September 30. Long-term debt, excluding current portion, was $574.0 million. The company reported no revolving-credit borrowings, approximately $5.0 million of letters of credit, and $445 million available under its $450 million facility.
- Capital returns: Nine-month dividends paid were $47.8 million; the quarterly dividend was $0.2525 per share. The company repurchased about 0.5 million shares for $15.8 million year to date, with about $74.2 million remaining under its authorization.
Material changes versus the prior comparable period
- Third-quarter revenue grew 3.6%; nine-month revenue grew 4.8%. Domestic revenue rose 4.7% for the quarter and 5.6% year to date. International revenue fell 16.4% and 10.3%, respectively, including unfavorable currency translation and the exit from a U.K. customer contract.
- Reported operating earnings and net income increased in both comparison periods. Prior-year results included a $14.9 million pretax loss on early debt retirement, which did not recur in 2015. Adjusted EPS, which excludes specified charges, also increased.
- Gross margin percentage improved modestly. SG&A was nearly flat in the quarter and up 2.1% year to date; depreciation and amortization increased.
- Operating cash flow rose substantially, primarily due to payment timing with vendors and improved net working capital. The prior-year financing cash flow included $547.7 million of debt proceeds; 2015 financing instead included repayment of $33.7 million under the credit facility.
- International revenue and gross margin were affected by currency translation. Nine-month currency impacts on International revenue and gross margin were $42.4 million and $34.0 million, respectively.
Outlook, commentary, risks and unusual items
- The filing gives no specific revenue, earnings or EPS guidance. Management said available cash generation and financing sources should be sufficient for anticipated working capital, capital expenditures, debt and lease payments, dividends, repurchases and other needs. It anticipated continuing quarterly dividends, subject to board discretion and business conditions.
- Management expected approximately $3.5 million of additional exit and realignment charges during the remainder of 2015 for activities already initiated.
- Acquisitions of Medical Action and ArcRoyal, completed in late 2014, expanded kitting capabilities; integration-related expenses continued in 2015. The filing reports their combined consideration as $261.6 million, net of cash acquired and including assumed debt.
- Key disclosed risks include pricing and competitive pressures, customer concentration and retention, supplier dependence, acquisition integration, healthcare regulation, foreign currency and international operations, information-system and cybersecurity disruption, litigation, and access to financing. Management reported no material changes to the risk factors in its 2014 Form 10-K and no material developments in previously reported legal proceedings.
- The company reported compliance with debt covenants and effective disclosure controls as of September 30, 2015. Its controls evaluation excluded the acquired businesses’ internal controls during the permitted post-acquisition period.
Important facts for investors to verify
- Confirm the intended issuer: the supplied filing is Owens & Minor, not Accendra Health.
- Review the company’s reported and adjusted results together, including the exclusions used in non-GAAP adjusted EPS.
- Assess whether Domestic growth can offset International contraction, customer-contract transitions and foreign-currency effects.
- Monitor working-capital movements, particularly receivables, inventory and supplier payment timing, which materially affected cash generation.
- Verify debt maturities, covenant headroom and access to the revolving facility; the filing reports $574.0 million of long-term debt and $445 million of unused facility capacity.
- Track expected restructuring charges, acquisition integration, ongoing legal contingencies and the sustainability of dividends and share repurchases.